<DOC>
	<DOCNO>NCT00853008</DOCNO>
	<brief_summary>Current therapeutic protocol adult ALL consider MRD together baseline risk factor ( age , WBC count , immunophenotype , cytogenetics ) speed response therapy treatment decision . On hand , systematic use allogeneic SCT adult patient ( pt ) Ph- HR-ALL still matter debate . The aim prospective study ALL-AR-03 Spanish PETHEMA Group evaluate response differentiate therapy ( chemotherapy allogeneic SCT ) accord early bone marrow blast clearance MRD level ( assess cytofluorometry end induction consolidation therapy ) HR Ph- adult ALL patient .</brief_summary>
	<brief_title>Treatment High Risk Adult Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>HR ALL include one follow baseline parameter : age 30-60 yr , WBC count &gt; 25x109/L 11q23 MLL rearrangement . Induction therapy include vincristine , prednisone daunorubicin 4 week . In pt slow cytologic response therapy ( â‰¥10 % blast bone marrow assess d14 ) intensify induction high dose ARA-C mitoxantrone administer . Early consolidation therapy include 3 cycle rotate cytotoxic drug include high-dose methotrexate , high-dose ARA-C high-dose asparaginase . Pts . slow cytologic response d14 MRD level &gt; 0.05 % consolidation assign allogeneic SCT ( relate unrelated ) standard cytologic response d14 MRD level &lt; 0.05 % consolidation receive 3 additional cycle delay consolidation ( identical early consolidation ) follow maintenance therapy 2yr CR .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>High risk ALL adult patient ( age &gt; 15 year ) treat previously Highrisk ALL : One following : Age 3060 yr. WBC count &gt; 25x109/L 11q23 ALL1/AF4 Very highrisk ALL : HR ALL one follow : Slow cytologic response ( &gt; 10 % blast BM d14 induction therapy ) . MRD &gt; 0.05 % ( flow cytometry ) end consolidation L3 ALL B mature ( sIg + ) ( 8 ; 14 ) , ( 2 ; 8 ) , ( 8 ; 22 ) . ALL Ph ( BCR/ABL ) positive . Bifenotipics ALL EGIL criterion . Indifferentiated ALL . Patients cardiac pathology Patients chronic liver disease activity fase Pulmonary disease Renal insufficiency due ALL Neurological disorder due ALL PS ( grade 3 4 ) due ALL .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>High-Risk ( HR )</keyword>
	<keyword>Philadelphia Chromosome-Negative</keyword>
</DOC>